Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone86-21-6163-2588
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$130,000.00
Profitability
Miscellaneous
Employees309
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable
Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions
What is Zai Lab's stock symbol?
Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."
When is Zai Lab's next earnings date?
What price target have analysts set for ZLAB?
5 equities research analysts have issued twelve-month target prices for Zai Lab's stock. Their forecasts range from $36.54 to $84.00. On average, they expect Zai Lab's share price to reach $52.89 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View Analyst Price Targets for Zai Lab.
What is the consensus analysts' recommendation for Zai Lab?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.
Has Zai Lab been receiving favorable news coverage?
News articles about ZLAB stock have trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zai Lab earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Zai Lab.
Are investors shorting Zai Lab?
Zai Lab saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,730,000 shares, an increase of 14.6% from the January 15th total of 1,510,000 shares. Based on an average daily volume of 261,700 shares, the days-to-cover ratio is presently 6.6 days. Currently, 2.9% of the company's shares are short sold. View Zai Lab's Current Options Chain.
Who are some of Zai Lab's key competitors?
Some companies that are related to Zai Lab include GALAPAGOS NV/S (GLPG), Ono Pharmaceutical (OPHLF), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Horizon Therapeutics (HZNP) and ACADIA Pharmaceuticals (ACAD).
What other stocks do shareholders of Zai Lab own?
Who are Zai Lab's key executives?
Zai Lab's management team includes the folowing people:
- Dr. Ying Du, Founder, Chairman & CEO (Age 53)
- Mr. Tao Fu, Pres, COO & Director (Age 47)
- Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
- Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
- Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)
When did Zai Lab IPO?
(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.
Who are Zai Lab's major shareholders?
Zai Lab's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Segantii Capital Management Ltd (5.80%), Baillie Gifford & Co. (5.23%), Bamco Inc. NY (3.78%), Credit Suisse AG (2.79%), Renaissance Technologies LLC (0.54%) and Jennison Associates LLC (0.44%).
Which institutional investors are selling Zai Lab stock?
ZLAB stock was sold by a variety of institutional investors in the last quarter, including Greenwoods Asset Management Ltd, Baillie Gifford & Co., Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Credit Suisse AG, Bamco Inc. NY, Pictet Asset Management Ltd. and Platinum Investment Management Ltd..
Which institutional investors are buying Zai Lab stock?
ZLAB stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, AXA, Segantii Capital Management Ltd, First Trust Advisors LP, State Street Corp and Matthews International Capital Management LLC.
How do I buy shares of Zai Lab?
Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Zai Lab's stock price today?
One share of ZLAB stock can currently be purchased for approximately $55.99.
How big of a company is Zai Lab?
Zai Lab has a market capitalization of $3.25 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.
What is Zai Lab's official website?
How can I contact Zai Lab?
Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]
MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)
| Community Ranking: | | 2.3 out of 5 ( ) |
| Outperform Votes: | | 176 (Thanks for Voting!) |
| Underperform Votes: | | 207 (Thanks for Voting!) |
| Total Votes: | | 383 |
